 |
Prospector
Profile
1221-09
|
| |
| Auriga Laboratories, Inc. |
NAICS |
325412 |
| 2029 Century Park East, Suite 1130
Los Angeles, CA 90067 |
Description |
Pharmaceuticals Mfg. |
| (678) 282-1600 |
Employees |
24 |
| http://www.aurigalabs.com/ |
Revenue |
(mil) |
3.1700 |
| |
Income |
(mil) |
-11.7100 |
| |
Assets |
(mil) |
10.6000 |
| |
Liability |
(mil) |
7.0400 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
IP Asset Sale
|
| |
|
Event:
Auriga Laboratories, Inc. disclosed in a regulatory filing with the Securities and Exchange Commission that it sold its wholly owned subsidiary, Stesso Pharmaceuticals LLC, to Malibu Pharma Inc. for $6 million. Stesso holds the license rights to sell and title to inventory of products Extendryl®, Levall®, and Dura-vent™.
|
| |
|
Intellectual Property:
The Company has applied for a registration of “Auriga Laboratories” as a trademark in the United States. In addition, it has applied for registrations of “Auriga Development,” “Auriga Pharmaceuticals” and “Stesso Pharmaceuticals” as trademarks in the United States. The Company has been licensed rights to use the trademarks Extendryl® and Levall® from their respective owners. In addition, it also has filed US trademark applications for the trademarks Akurza™, Zinx™, Xyralid™, Aquoral™, Dura-Vent™, Orchestrated Therapy™, The Doctor Recommended Zinc™, Innovation in Oral Hydration™ and Our Business is Your Health™. The Company has obtained, and expect to continue to seek, licenses to patents and patent applications and other proprietary rights from others. The Company has six patent applications or provisional patent applications pending in the US Patent and Trademark Office and plans to use Patent Cooperation Treaty filings in an attempt to expand coverage of the pending US patent applications to individual countries outside the United States. [SEC Filing 10-K 03-30-07]
|
| |
|
Description:
The Company develops pharmaceutical products for the respiratory, dermatology and psychiatry markets. Its portfolio consists of Aquoral™, Zinx™, Akurza™, Xyralid™, Extendryl® and Levall® product lines.
|
| |
|
Officers:
Philip S. Pesin (Chair & CEO); Charles R. Bearchell (CFO); Andrew Shales (COO & Sec.); Alan Roberts (Chief Scientific Officer); Dayne Wagoner (Dir.); Brian P. Alleman (Dir.); Steve C. Glover (Dir.); Trevor K. Pokorney (Dir.)
|
| |
|
Auditor:
Williams & Webster PS
|
| |
|
Securities:
Common Stock Symbol ARGA.OB; OTC BB;
52,094,249 common shares outstanding as of October 26, 2007.
|
| |
| |
| |
| return to main page |
|
|
